MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.
复制标题
MicroRNA：用于诊断，预后，治疗预测和乳腺癌治疗工具的新生物标志物。
DOI：
10.7150/thno.11543
复制
发表时间：
2015
期刊：
影响因子：
12.4
通讯作者：
Castiglioni I
中科院分区：
文献类型：
--
作者：
Bertoli G;Cava C;Castiglioni I
microRNA（miRNAs）的失调参与了包括乳腺癌（BC）在内的多种人类癌症的发生和发展，因为已经发现有力的证据表明miRNAs可以作为癌基因或肿瘤抑制基因。本文综述了miRNAs在乳腺癌诊断、预后和治疗中的作用。基于在过去十年中获得的结果，一些miRNA正在成为用于诊断的BC的生物标志物（即，miR-9、miR-10b和miR-17 - 5p）、预后（即，miR-148a和miR-335）和治疗结果的预测（即，miR-30c、miR-187和miR-339 - 5p），并且在控制BC标志性功能如侵袭、转移、增殖、静息死亡、凋亡和基因组不稳定性中具有重要作用。其他miRNA作为用于BC患者的个性化管理的新的、容易获得的、负担得起的、非侵入性工具是令人感兴趣的，因为它们在体液中循环（例如，miR-155和miR-210）。特别是，循环中的多种miRNA谱显示出比BC中的单个miRNA更好的诊断和预后性能以及更好的灵敏度。新的基于miRNA的药物也是有希望的BC疗法（例如，miR-9、miR-21、miR34a、miR145和miR150）和其他miRNA在调节对其他非miRNA治疗的应答中显示出基本作用，能够增加它们的功效（例如，miR-21、miR34a、miR195、miR200c和miR203与化疗组合）。
Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as oncogenes or tumor suppressor genes. This review presents the state of the art on the role of miRNAs in the diagnosis, prognosis, and therapy of BC. Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335), and prediction of therapeutic outcomes (i.e., miR-30c, miR-187, and miR-339-5p) and have important roles in the control of BC hallmark functions such as invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs are of interest as new, easily accessible, affordable, non-invasive tools for the personalized management of patients with BC because they are circulating in body fluids (e.g., miR-155 and miR-210). In particular, circulating multiple miRNA profiles are showing better diagnostic and prognostic performance as well as better sensitivity than individual miRNAs in BC. New miRNA-based drugs are also promising therapy for BC (e.g., miR-9, miR-21, miR34a, miR145, and miR150), and other miRNAs are showing a fundamental role in modulation of the response to other non-miRNA treatments, being able to increase their efficacy (e.g., miR-21, miR34a, miR195, miR200c, and miR203 in combination with chemotherapy).